RxDoctor Payments Data

Deborah Witkin, MD

Ophthalmology · Waterville, MENPI 1457732299

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $507 of the $597 with a category attached, or 85.0%. 7 manufacturers reported payments, led by Johnson & Johnson Surgical Vision, Inc. at 44.4% of the total. Reporting peaked in 2024 at $189 and has fallen 76.1% since, to $45 in 2025.

$597in general payments, 2019–2025

Across 18 payments — averaging $33.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson Surgical Vision, Inc.$265
  • Alcon$114
  • Ivantis, Inc$83
  • Regeneron Healthcare Solutions, Inc.$50
  • AbbVie$40
  • Bausch & Lomb Americas Inc.$26
  • plus $19 from 1 others

What the payments were for

  • Food & beverage$50785%
  • Education$9015%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$597 in reported general payments places this provider in the 60th percentile of 74 ophthalmology providers in Maine.

See all ophthalmology providers in Maine

Medicare billing

Part B allowed, 2024
$2,328,477
Medicare patients
683
Services billed
18,701

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RocklatanNetarsudil Mesylat/Latanoprost119$79,490
LumiganBimatoprost117$71,245
RhopressaNetarsudil Mesylate74$46,964
CombiganBrimonidine Tartrate/Timolol71$31,685
RestasisCyclosporine15$28,326
Prednisolone Acetate631$25,930
SimbrinzaBrinzolamide/Brimonidine Tart78$22,470
Brimonidine Tartrate221$18,588
Brinzolamide98$17,934
Alphagan PBrimonidine Tartrate26$13,166
Travoprost58$10,273
TafluprostTafluprost/Pf55$9,956
Latanoprost596$8,147
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol50$6,924
Dorzolamide-TimololDorzolamide/Timolol/Pf28$4,603

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Combigan, Restasis, Alphagan P$40$144,423229 claims
AlconSimbrinza$114$22,47078 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 74 ophthalmology providers in Maine.

Other ophthalmology in Waterville

See the full list for Maine

Where these figures come from

Is this you, or does something look wrong? →